FCGR3A and carcinoma: An evolution of TriKE format is TetraKE, which has been described to simultaneously engage EpCAM and CD133 for targeting carcinoma cells and cancer stem cells, along with a CD16-engaging moiety and IL-15 for NK cell expansion 59.